Das Medizinportal     Aktuelles für medizinische Fachkreise
Menü

Das Medizinportal     Aktuelles für medizinische Fachkreise

Literatur:

Retinale Venenverschlüsse: Switch ja oder nein? (Seite12-19)
Interview mit L.-O. Hattenbach

  1. Tadayoni R, Waldstein SM, Boscia F, Gerding H, Gekkieva M, Barnes E, Das Gupta A, Wenzel A, Pearce I; BRIGHTER Study Group. Sustained Benefits of Ranibizumab with or without Laser in Branch Retinal Vein Occlusion: 24-Month Results of the BRIGHTER Study. Ophthalmology. 2017 Dec; 124(12):1778-1787. doi: 10.1016/j.ophtha.2017.06.027. Epub 2017 Aug 12. Erratum in: Ophthalmology. 2018 Mar;125(3):463.
  2. Clark WL, Boyer DS, Heier JS, Brown DM, Haller JA, Vitti R, Kazmi H, Berliner AJ, Erickson K, Chu KW, Soo Y, Cheng Y, Campochiaro PA. Intravitreal Aflibercept for Macular Edema Following Branch Retinal Vein Occlusion: 52-Week Results of the VIBRANT Study. Ophthalmology. 2016 Feb;123(2):330-6. doi: 10.1016/j.ophtha.2015.09.035. Epub 2015 Oct 30.
  3. Pielen A1, Mirshahi A, Feltgen N, Lorenz K, Korb C, Junker B, Schaefer C, Zwiener I, Hattenbach LO; RABAMES Study Group. Ranibizumab for Branch Retinal Vein Occlusion Associated Macular Edema Study (RABAMES): six-month results of a prospective randomized clinical trial. Acta Ophthalmol. 2015 Feb;93(1):e29-37. doi: 10.1111/aos.12488. Epub 2014 Jul 8.
  4. Hattenbach LO1, Feltgen N2, Bertelmann T2,3, Schmitz-Valckenberg S4, Berk H5, Eter N6, Lang GE7, Rehak M8,9, Taylor SR10, Wolf A11, Weiss C3, Paulus EM3, Pielen A12, Hoerauf H2; COMRADE-B Study Group. Head-to-head comparison of ranibizumab PRN versus single-dose dexamethasone for branch retinal vein occlusion (COMRADE-B). Acta Ophthalmol. 2018 Feb;96(1):e10-e18. doi: 10.1111/ aos.13381. Epub 2017 Mar 2.
  5. Hoerauf H1, Feltgen N2, Weiss C3, Paulus EM3, Schmitz-Valckenberg S4, Pielen A5, Puri P6, Berk H7, Eter N8, Wiedemann P9, Lang GE10, Rehak M11, Wolf A12, Bertelmann T13, Hattenbach LO14; COMRADE-C Study Group. Clinical Efficacy and Safety of Ranibizumab Versus Dexamethasone for Central Retinal Vein Occlusion (COMRADE C): A European Label Study. Am J Ophthalmol. 2016 Sep;169:258-267. doi: 10.1016/j.ajo.2016.04.020. Epub 2016 May 7.
  6. Hanhart J, Rozenman Y, Comparison of Intravitreal Ranibizumab, Aflibercept, and Dexamethasone Implant after Bevacizumab Failure in Macular Edema Secondary to Retinal Vascular Occlusions, Ophthalmologica 2017; 238:110–118
  7. Hwang HS, Chae JB, Kim JY, Kim DY, Association Between Hyperreflective Dots on Spectral-Domain Optical Coherence Tomography in Macular Edema and Response to Treatment, Invest Ophthalmol Vis Sci. 2017 Nov 1;58(13):5958-5967. doi: 10.1167/iovs.17-22725.

Irvine-Gass-Syndrom: Studienlage und Praxis (Seite 20-25)
Sigrid Freissinger, Wolfgang J. Mayer, Efstathios Vounotrypidis

  1. Irvine Sr. A newly defined vitreous syndrome following cataract surgery. Am J Ophthalmol. 1953;36(5):599-619. doi:10.1016/ 0002-9394(53)90302-X.
  2. Chu CJ, Johnston RL, Buscombe C, Sallam AB, Mohamed Q, Yang YC. Risk Factors and Incidence of Macular Edema after Cataract Surgery A Database Study of 81984 Eyes. Ophthalmology. 2016; 123(2):316-323. doi:10.1016/ j.ophtha. 2015.10.001.
  3. Wolter JR. The Histopathology of Cystoid Macular Edema. Ophthalmology. 1978;3347:33-47.
  4. Reese  AB, Jones IS, Cooper WC. Macular changes secondary to vitreous traction. Trans Am Ophthalmol Soc. 1966;64:123-134.
  5. von Lany H, Mahmood S, James CRH, et al. Displacement of nuclear fragments into the vitreous complicating phacoemulsification surgery in the UK: clinical features, outcomes and management. Br J Ophthalmol. 2008;92(4):493-495. doi:10.1136/ bjo.2007.114637.
  6. Ursell PG, Spalton DJ, Whitcup SM, Nussenblatt RB. Cystoid macular edema after phacoemulsification: relationship to blood–aqueous barrier damage and visual acuity. J Cataract Refract Surg. 1999;25(11):1492-1497. doi:10.1016/S0886-3350 (99)00196-0.
  7. Guo S, Patel S, Baumrind B, et al. Management of pseudophakic cystoid macular edema. Surv Ophthalmol. 2015;60(2):123-137. doi:10.1016/j.survophthal.2014. 08.005.
  8. Packer M, Lowe J, Fine H. Incidence of acute postoperative cystoid macular edema in clinical practice. J Cataract Refract Surg. 2012;38(12):2108-2111. doi:10. 1016/j.jcrs.2012.07.029.
  9. Shelsta HN, Jampol Leem. Pharmacologic Therapy of Pseudophakic Macular  Edema 2010 Update. Update. 2010:4-12.
  10. Ritter M, Sacu S, Matt G, et al. Use of systemic steroid after successful macular surgery in eyes with epiretinal membrane: A randomized, controlled clinical study. Eye. 2011;25(10):1284-1293. doi:10. 1038/eye.2011.190.
  11. Daien V, Papinaud L, Domerg C, Lacombe S, Daures JP, Villain M. Incidence and Characteristics of Cystoid Macular Edema after Cataract Surgery. Ophthalmology. 2016;123(3):663-664. doi:10.1016 /j.ophtha.2015.10.009.
  12. Hoffman RS, Braga-Mele R, Donaldson K, et al. Cataract surgery and nonsteroidal antiinflammatory drugs. 2016:1368-1379. doi:10.1016/j.jcrs.2016. 06.006.
  13. Asano S, Miyake K, Ota I, et al. Reducing angiographic cystoid macular edema and blood-aqueous barrier disruption after small-incision phacoemulsification and foldable intraocular lens implantation. Multicenter prospective randomized comparison of topical diclofenac 0.1% and betamethasone 0.1%. J Cataract Refract Surg. 2008;34(1):57-63. doi:10.1016/j.jcrs.2007.08.030.
  14. Katzung B, Chrousos GP, Masters S, Trevor A. Chapter 39. Adrenocorticosteroids & Adrenocortical Antagonists. Basic Clin Pharmacol. 1995:592-607. 0-www.accessmedicine.com.library.lausys.georgetown.edu/popup.aspx= 4520663 & print = yes_chapter.
  15. McCuen BW, Bessler M, Tano Y, Chandler D, Machemer R. The lack of toxicity of intravitreally administered triamcinolone acetonide. Am J Ophthalmol. 1981;91(6):785-788. www. ncbi.nlm.nih.gov/pubmed/ 7246702?ordinalpos =2 & itool = EntrezSystem2.PEntrez.Pubmed. Pubmed_ResultsPanel.Pubmed_ RVDocSum.
  16. Chin H-S, Park T-S, Moon Y-S, Oh J-H. Difference in Clearance of Intravitreal Triamcinolone Acetonide Between Vitrectomized and Nonvitrectomized Eyes. Retina. 2005;25(5):556-560. doi:10.1097/ 00006982-200507000-00002.
  17. Mayer W, Kurz S, Wolf A, et al. Dexamethasone implant as an effective treatment option for macular edema due to Irvine-Gass syndrome. J Cataract Refract Surg. 2015.
  18. Brynskov T, Laugesen CS, Halborg J, Kemp H, Sørensen TL. Longstanding refractory pseudophakic cystoid macular edema resolved using intravitreal 0.7 mg dexamethasone implants. Clin Ophthalmol. 2013;7:1171-1174. doi:10. 2147/OPTH.S46399.
  19. Chang-Lin JE, Burke JA, Peng Q, et al. Pharmacokinetics of a sustained-release dexamethasone intravitreal implant in vitrectomized and nonvitrectomized eyes. Investig Ophthalmol Vis Sci. 2011;52(7):4605-4609. doi:10.1167 /iovs.10-6387.
  20. Kuppermann B, MD P, Blumenkranz M, et al. Randomized Controlled Study of an Intravitreous Dexamethasone Drug Delivery System in Patients With Persistent Macular Edema. Arch Ophthalmol. 2007;125(3):309-317. doi:10.1001/archopht. 125. 3.309.
  21. Haller JA, Bandello F, Belfort R, et al. Randomized, Sham-Controlled Trial of Dexamethasone Intravitreal Implant in Patients with Macular Edema Due to Retinal Vein Occlusion. Ophthalmology. 2010;117(6):1134-1146.e3. doi: 10.1016/j.ophtha.2010.03.032.
  22. Medeiros MD, Alkabes M, Navarro R, Garcia-Arumí J, Mateo C, Corcóstegui B. Dexamethasone intravitreal implant in vitrectomized versus nonvitrectomized eyes for treatment of patients with persistent diabetic macular edema. J Ocul Pharmacol Ther. 2014;30(9):709-716. doi:10.1089/ jop.2014.0010.
  23. Banerjee PJ, Quartilho A, Bunce C, et al. Slow-Release Dexamethasone in Proliferative Vitreoretinopathy: A Prospective, Randomized Controlled Clinical Trial. Ophthalmology. 2017;124(6):757-767. doi:10.1016/j.ophtha.2017. 01.021.
  24. Gillies MC, Lim LL, Campain A, et al. A randomized clinical trial of intravitreal bevacizumab versus intravitreal dexamethasone for diabetic macular edema: The Bevordex  study. Ophthalmology. 2014;121(12):2473-2481. doi:10. 1016/j.ophtha.2014.07.002.
  25. Tamm ER, Braunger BM, Fuchshofer R (2015) Intraocular Pressure and the Mechanisms Involved in Resistance of the Aqueous Humor Flow in the Trabecular Meshwork Outflow Pathways. Progress in molecular biology and translational science 134:301-314
  26. Reibaldi M, Longo A. Widening use of dexamethasone implant for the treatment of macular edema. 2017:2359-2372.
  27. Hattenbach L-O, Springer-Wanner C, Hoerauf H, et al. Intravitreal Sustained-Release Steroid Implants for the Treatment of Macular Edema following Surgical Removal of Epiretinal Membranes. Ophthalmologica. 2017;237:232-237.
  28. Furino C, Boscia F, Recchimurzo N, Sborgia C, Alessio G. Intravitreal dexamethasone implant for refractory macular edema secondary to vitrectomy for macular pucker. Retina. 2014;34(8):1612-1616. doi:10.1097/IAE.000000 0000000105.
  29. Kessel L, Tendal B, Jørgensen KJ, et al. Post-cataract prevention of inflammation and macular edema by steroid and nonsteroidal anti-inflammatory eye drops: A systematic review. Ophthalmology. 2014;121(10):1915-1924. doi:10.1016/j.ophtha.2014.04. 035.
  30. Cardascia N, Palmisano C, Centoducati T, Alessio G. Topical nonsteroidal anti-inflammatory drugs as adjuvant therapy in the prevention of macular edema after cataract surgery. Int Ophthalmol. 2017;37(5):1127-1131. doi:10.1007/s10792-016-0374-5.
  31. Hariprasad SM, Akduman L, Clever J a., Ober M, Recchia FM, Mieler WF. Treatment of cystoid macular edema with the new-generation NSAID nepafenac 0.1%. Clin Ophthalmol. 2009;3(1):147-154. doi:10.2147/OPTH.S4684.
  32. Lindstrom R, Kim T. Ocular permeation and inhibition of retinal inflammation: An examination of data and expert opinion on the clinical utility of nepafenac. Curr Med Res Opin. 2006;22(2):397-404. doi:10.1080/140349405 00327802.
  33. Walters T, Raizman M, Ernest P, Gaxton J, Lehmann R. No TitlIn vivo pharmacokinetics and in vitro pharmacodynamics of nepafenac, amfenac, ketorolac, and bromfenac.e. Cataract Refract Surg. 2007;33 (9):1539-1545.
  34. Mylonas G, Georgopoulos M, Malamos P, et al. Comparison of Dexamethasone Intravitreal Implant with Conventional Triamcinolone in Patients with Postoperative Cystoid Macular Edema. Curr Eye Res. 2017;42(4):648-652. doi:10. 1080/02713683.2016.1214968.
  35. Degoumois A, Akesbi J, Laurens C, et al. Efficacité des implants intravitréens de dexaméthasone dans l“édéme maculaire hors occlusions veineuses: Résultats sur une cohorte de 80 patients. J Fr Ophtalmol. 2015;38(2):126-133. doi:10.1016/j.ophtha.2014. 04.024.
  36. Shaikh AH, Petersen MR, Sisk RA, Foster RE, Riemann CD, Miller DM. Comparative effectiveness of the dexamethasone intravitreal implant in vitrectomized and non-vitrectomized eyes with macular edema secondary to central retinal vein occlusion. Ophthalmic Surg Lasers Imaging Retina. 2013;44(1):28-33. doi:10.3928/ 23258160-20121221-09.
  37. Thanos A, Todorich B, Yonekawa Y, et al. Dexamethasone Intravitreal Implant for the Treatment of Recalcitrant Macular Edema After Rhegmatogenous Retinal Detachment Repair. Retina. 2017. doi:10.1097/ IAE.000000000000 1720.
  38. Tsang SH, Mahajan VB. Combined Vitrectomy And Intravitreal Dexamethasone.
  39. Guidi G, Casini G, Ripandelli G, Lazzeri S. 25-Gauge Vitrectomy And Macular Is Intraoperative Sustained-release Dexamethasone a Real Treatment Option:1-7.

Polypoidale choroidale Vaskulopathien: Diagnostik als Herausforderung
(Seite 26-29)
Maria-Andreea Gamulescu

  1. Kleiner RC, Brucker AJ, Johnston RL. The posterior uveal bleeding syndrome. Retina. 1990; 10(1): 9-17.
  2. Stern RM, Zakov AN, Zegarra N, et al. Multiple recurrent serosanguineous retinal pigment epithelial detachments in black women. Am J Ophthalmol. 1985; 10: 560-569.
  3. Uyama M, Matsubara T, Fukushima I, et al. Idiopathic polypoidal choroidal vasculopathy in Japanese patients. Arch Ophthalmol. 1999; 117(8): 1035-1042.
  4. Yannuzzi LA, Sorenson J, Spaide RF, et al. Idiopathic Polypoidal Choroidal Vasculopathy (IPCV). Retina. 1990; 10: 1-8.
  5. Imamura Y, Engelbert M, Iida T, et al. Polypoidal choroidal vasculopathy. Survey of Opthalmology. 2010; 55: 501-515.
  6. Uyama M, Wada M, Nagai Y, et al. Polypoidal choroidal vasculopythy: natural history. Am J. Ophthalmol. 2002; 133: 639-648.
  7. Yannuzzi LA, Ciardella A, Spaide RF, et al. The expanding clinical spectrum of idiopathic polypoidal vasculopathy. Arch Ophthalmol. 1997; 115: 478-485.
  8. Spaide RF, Yannuzzi LA, Slakter JS, et al. Indocyanine green videoangiography of idiopathic polypoidal choroidal vasculopathy. Retina. 1995; 15(2): 100-110.
  9. Okubo A, Sameshima M, Sakamoto T. Choroidal venous pulsations at an arterio-venous crossing in polypoidal choroidal vasculopathy. Korean J Ophthalmol. 2013; 27(5): 384-387.
  10. Gallego-Pinazo R, Dolz-Marco R, Gómez-Ulla F, et al. Pachychoroid diseases of the macula. Med Hypothesis Discov Innov Ophthalmol. 2014; 3(4): 111-115.
  11. Sato T, Kishi S, Watanabe G, et al. Tomographic features of branching vascular networks in polypoidal choroidal vasculopathy. Retina. 2007; 27(5): 589-594.
  12. Otsuji T, Takahashi K, Fukushima I, Uyama M. Optical coherence tomographic findings of idiopathic polypoidal choroidal vasculopathy. Ophthalmic Surg Lasers. 2000; 31(3): 210-214.
  13. Sho K, Takahashi K, Yamada H, et al. Polypoidal choroidal vasculopathy: incidence, demographic features and clinical characteristics. Arch Ophthalmol. 2003; 121(10): 1392-1396.
  14. Lafaut BA, Leys AM, Snyers B, et al. Polypoidal choroidal vasculopathy in Caucasians. Graefes Arch Clin Exp Ophthalmol. 2000; 238(9): 752-759.
  15. Gomi F, Sawa M, Sakaguchi H, et al. Efficacy of intravitreal bevacizumab for choroidal vasculopathy. Br J Ophthalmol. 2008; 92(1): 70-73.
  16. Kokame GT, Yeung L, Teramoto K, et al. Polypoidal choroidal vasculopathyexudation and hemorrhage: results of monthly ranibizumab therapy at one year. Int J Ophthalmol. 2014; 231(2): 94-102.
  17. Ogura Y, Terasaki H, Gomi F, et al. Efficacy and safety of intravitreal aflibercept injection in wet age-related macular degeneration: outcomes in the Japanese subgroup of the VIEW 2 study. Br J Opthalmol. 2015; 99(1): 92-97.
  18. Yuzawa M, Mori R, Haruyama M. A study of laser photocoagulation for polypoidal choroidal vasculopathy. Jpn J Ophthalmol. 2003; 47(4): 379-384.
  19. Silva RM, Figueura J, Cachulo ML, et al. Polypoidal choroidal vasculopathy and photodynamic therapy with verteporfin. Graefes Arch Clin Exp Opthalmol. 2005; 243(10): 973-979.
  20. Koh A, Lai TY, Takahashi K, et al. Efficacy and safety of ranibizumab with or without verteporfin photodynamic therapy for polypoidal choroidal vasculopathy: a randomized clinical trial. JAMA Ophthalmol. 2017; 135(11): 1206-1213.
  21. Lee WK, Tomohire I, Ogura Y, et al. Efficacy and safety of intravitreal aflibercept for polypoidal choroidal vasculopathy in the PLANET study: a randomized clinical trial. JAMA Ophthalmol 2018; doi:10.1001/jamaophthalmol.2018.1804.
  22. Hatz K, Prünte C. Polypoidal choroidal vasculopathy in Caucasian patients with presumed neovascular age-related macular degeneration and poor ranibizumab response. Br J Ophthalmol. 2014; 98(2): 188-194.

Update – Aus den Unternehmen

Allergan: 9. Retina-Forum (Seite 42/43)

  1. Chen E et al. Curr Med Res Opin 2010; 26: 1587–97
  2. EURetina-Guideline: Schmidt-Erfurth U et al. Ophthalmologica 2017; 237(4): 185–222
  3. Boyer DS et al. Ophthalmology 2014; 121(10): 1904–14
  4. Khan Z et al. Retina 2017; 48: 160–6
  5. Malclès A et al. Retina 2017; 37(4): 753–60
  6. Gonzalez VH et al. Am J Ophthalmol 2016; 172: 72–9
  7. Sivaprasad S et al. J Clin Opthalmol 2016; 10: 939–46
  8. Ehlken C et al. Clin Ophthalmol 2017; 12: 13–20
  9. Pohlmann D. et al. Ophthalmology 2018 Feb 16. pii: S0161-6420(17)31574-9

Retina Implant AG (Seite 44)

  1. Schatz et al.: Transcorneal Electrical Stimulation for Patients with Retinitis pigmentosa: A Prospective, Randomized, Sham-Controlled Exploratory Study. Invest Ophthalmol Vis Sci. 2011; 52: 4485-4496.
  2. Schatz et al.: Transcorneal Electrical Stimulation for Patients with Retinitis Pigmentosa: A Prospective, Randomized, Sham-Controlled Follow-up Study Over 1 Year. Invest Ophthalmol Vis Sci. 2017; 58: 257-269
  3. Stingl K et al.: Interim Results of a Multicenter Trial with the New Electronic Subretinal Implant Alpha AMS in 15 Patients Blind from Inherited Retinal Degenerations. Front. Neurosci. 2017; 11:445.